Cargando…

The prognostic value of troponin T and N‐terminal pro B‐type natriuretic peptide, alone and in combination, in heart failure patients with and without diabetes

AIMS: We examined the prognostic importance of N‐terminal pro B‐type natriuretic peptide (NT‐proBNP) and troponin T (TnT) in heart failure patients with and without diabetes. METHODS AND RESULTS: We measured NT‐proBNP and TnT in the biomarker substudy of the Prospective Comparison of ARNI With ACEI...

Descripción completa

Detalles Bibliográficos
Autores principales:	Rørth, Rasmus, Jhund, Pardeep S., Kristensen, Søren L., Desai, Akshay S., Køber, Lars, Rouleau, Jean L., Solomon, Scott D., Swedberg, Karl, Zile, Michael R., Packer, Milton, McMurray, John J.V.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley & Sons, Ltd 2018
Materias:	Prognosis
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6607514/ https://www.ncbi.nlm.nih.gov/pubmed/30537261 http://dx.doi.org/10.1002/ejhf.1359

Ejemplares similares

Urinary cGMP (Cyclic Guanosine Monophosphate)/BNP (B-Type Natriuretic Peptide) Ratio, Sacubitril/Valsartan, and Outcomes in Heart Failure With Reduced Ejection Fraction: An Analysis of the PARADIGM-HF Trial
por: Butt, Jawad H., et al.
Publicado: (2023)

Relationship between duration of heart failure, patient characteristics, outcomes, and effect of therapy in PARADIGM‐HF
por: Yeoh, Su E., et al.
Publicado: (2020)

Anthropometric measures and adverse outcomes in heart failure with reduced ejection fraction: revisiting the obesity paradox
por: Butt, Jawad H, et al.
Publicado: (2023)

Effect of sacubitril/valsartan on recurrent events in the Prospective comparison of ARNI with ACEI to Determine Impact on Global Mortality and morbidity in Heart Failure trial (PARADIGM‐HF)
por: Mogensen, Ulrik M., et al.
Publicado: (2018)

Dementia‐related adverse events in PARADIGM‐HF and other trials in heart failure with reduced ejection fraction
por: Cannon, Jane A., et al.
Publicado: (2016)

Sacubitril/valsartan reduces serum uric acid concentration, an independent predictor of adverse outcomes in PARADIGM‐HF
por: Mogensen, Ulrik M., et al.
Publicado: (2017)

Serum potassium in the PARADIGM‐HF trial
por: Ferreira, João Pedro, et al.
Publicado: (2020)

Efficacy of an implantable cardioverter-defibrillator in patients with diabetes and heart failure and reduced ejection fraction
por: Rørth, Rasmus, et al.
Publicado: (2019)

Risk Related to Pre–Diabetes Mellitus and Diabetes Mellitus in Heart Failure With Reduced Ejection Fraction: Insights From Prospective Comparison of ARNI With ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure Trial
por: Kristensen, Søren L., et al.
Publicado: (2016)

Efficacy and safety of LCZ696 (sacubitril-valsartan) according to age: insights from PARADIGM-HF
por: Jhund, Pardeep S., et al.
Publicado: (2015)

Initiation of domiciliary care and nursing home admission following first hospitalization of heart failure patients: a nationwide cohort study
por: Rørth, Rasmus, et al.
Publicado: (2018)

Reduced loop diuretic use in patients taking sacubitril/valsartan compared with enalapril: the PARADIGM‐HF trial
por: Vardeny, Orly, et al.
Publicado: (2019)

Effect of sacubitril/valsartan on investigator‐reported ventricular arrhythmias in PARADIGM‐HF
por: Curtain, James P., et al.
Publicado: (2022)

Efficacy of sacubitril/valsartan vs. enalapril at lower than target doses in heart failure with reduced ejection fraction: the PARADIGM‐HF trial
por: Vardeny, Orly, et al.
Publicado: (2016)

Insulin treatment and clinical outcomes in patients with diabetes and heart failure with preserved ejection fraction
por: Shen, Li, et al.
Publicado: (2019)

Development and external validation of prognostic models to predict sudden and pump-failure death in patients with HFrEF from PARADIGM-HF and ATMOSPHERE
por: Shen, Li, et al.
Publicado: (2021)

Predicting stroke in heart failure and reduced ejection fraction without atrial fibrillation( )
por: Kondo, Toru, et al.
Publicado: (2022)

Clinical Characteristics and Outcomes of Patients With Heart Failure With Reduced Ejection Fraction and Chronic Obstructive Pulmonary Disease: Insights From PARADIGM‐HF
por: Ehteshami‐Afshar, Solmaz, et al.
Publicado: (2021)

Effect of sacubitril/valsartan vs. enalapril on changes in heart failure therapies over time: the PARADIGM‐HF trial
por: Bhatt, Ankeet S., et al.
Publicado: (2021)

Baseline characteristics and treatment of patients in Prospective comparison of ARNI with ACEI to Determine Impact on Global Mortality and morbidity in Heart Failure trial (PARADIGM-HF)
por: McMurray, John J V, et al.
Publicado: (2014)

Dual angiotensin receptor and neprilysin inhibition as an alternative to angiotensin-converting enzyme inhibition in patients with chronic systolic heart failure: rationale for and design of the Prospective comparison of ARNI with ACEI to Determine Impact on Global Mortality and morbidity in Heart Failure trial (PARADIGM-HF)
por: McMurray, John J. V., et al.
Publicado: (2013)

Prevalence of Prediabetes and Undiagnosed Diabetes in Patients with HFpEF and HFrEF and Associated Clinical Outcomes
por: Kristensen, Søren L., et al.
Publicado: (2017)

Differential clinical characteristics and prognosis of intraventricular conduction defects in patients with chronic heart failure
por: Cinca, Juan, et al.
Publicado: (2013)

Effects of sacubitril/valsartan on glycemia in patients with diabetes and heart failure: the PARAGON-HF and PARADIGM-HF trials
por: Wijkman, Magnus O., et al.
Publicado: (2022)

Developing and validating models to predict sudden death and pump failure death in patients with heart failure and preserved ejection fraction
por: Shen, Li, et al.
Publicado: (2020)

Heart failure with reduced ejection fraction: comparison of patient characteristics and clinical outcomes within Asia and between Asia, Europe and the Americas
por: Dewan, Pooja, et al.
Publicado: (2018)

Initiation of domiciliary care and nursing home admission following first hospitalization for heart failure, stroke, chronic obstructive pulmonary disease or cancer
por: Rørth, Rasmus, et al.
Publicado: (2021)

Prediction of thrombo‐embolic risk in patients with hypertrophic cardiomyopathy (HCM Risk‐CVA)
por: Guttmann, Oliver P., et al.
Publicado: (2015)

The Ocular Trauma Score
por: Scott, Robert
Publicado: (2015)

Implementing and applying the Ocular Trauma Score: the challenges
por: Murray, Desirée C
Publicado: (2015)

A simple validated method for predicting the risk of hospitalization for worsening of heart failure in ambulatory patients: the Redin‐SCORE
por: Álvarez‐García, Jesús, et al.
Publicado: (2015)

Phase of Illness in palliative care: Cross-sectional analysis of clinical data from community, hospital and hospice patients
por: Mather, Harriet, et al.
Publicado: (2017)

External validation and clinical utility of a prediction model for 6-month mortality in patients undergoing hemodialysis for end-stage kidney disease
por: Forzley, Brian, et al.
Publicado: (2017)

Combination of late gadolinium enhancement and genotype improves prediction of prognosis in non‐ischaemic dilated cardiomyopathy
por: Mirelis, Jesús G., et al.
Publicado: (2022)

Post hoc analyses of SHIFT and PARADIGM‐HF highlight the importance of chronic Chagas' cardiomyopathy Comment on: “Safety profile and efficacy of ivabradine in heart failure due to Chagas heart disease: a post hoc analysis of the SHIFT trial” by Bocchi et al.
por: Ramires, Felix J.A., et al.
Publicado: (2018)

Diabetes and pre‐diabetes in patients with heart failure and preserved ejection fraction
por: Jackson, Alice M., et al.
Publicado: (2022)

Drug therapy for heart failure with reduced ejection fraction: what is the ‘right’ dose?
por: Kondo, Toru, et al.
Publicado: (2022)

Geographic variations in the PARADIGM-HF heart failure trial
por: Kristensen, Søren Lund, et al.
Publicado: (2016)

Eligibility for pharmacological therapies in heart failure with reduced ejection fraction: implications of the new Chronic Kidney Disease Epidemiology Collaboration creatinine equation for estimating glomerular filtration rate
por: Butt, Jawad H., et al.
Publicado: (2022)

Right ventricular dysfunction in patients with new‐onset heart failure: longitudinal follow‐up during guideline‐directed medical therapy
por: Ansari Ramandi, Mohammad Mostafa, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_dnesnpa4fbgebjuohinpi9riv5